Added to YB: 2026-05-25
Pitch date: 2026-05-21
REPL [neutral]
Replimune Group, Inc.
Author Info
Earnings Edge shares detailed earnings previews and recaps delivered lightning fast. Sign up for the newsletter.
Company Info
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer.
Market Cap
$405.4M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.67
P/E
-1.43
EV/Sales
N/A
Sector
Biotechnology
Category
turnaround
Earnings Edge for Friday: Replimune Group (REPL)
REPL (earnings): Phase 3 IGNYTE-3 trial in 400 anti-PD-1 refractory melanoma patients remains key catalyst after 2nd CRL killed RP1 near-term commercial path. ASCO posters May 29-Jun 2 show 3yr OS data. $269M cash runs to Q1 2027. CEO said can't develop RP1 w/o accelerated approval, job cuts coming. Analysts cut PTs to $2-4. Securities probes active, $76M debt, $70M/qtr burn. May 21 call critical for restructuring plan.
Read full article (2 min)